Status: Recruiting
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to \< 18 years with advanced leukemias, lymphomas, and solid tumors.
Participants needed: 70
Trial details
Phase: Phase 1, Phase 2Age: 1-17Biological sex: AllType: InterventionalSponsor: Incyte Biosciences International SàrlUpdated: Apr 16, 2026Locations: 23
Eligibility criteria
Karnofsky performance status ≥ 40% for participants ≥ 16 years old or Lansky Pla... [+34]